Gilotrif is effective in the treatment of advanced stage lung cancer, with locally advanced or metastatic non-small cell cancer with mutations in the epidermal growth factor receptor gene in adult and pre-existing patients. that have not been treated with an EGFR tyrosine kinase inhibitor.